These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 35993617)
1. Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach. Abdel-Hafez A; Scott IA; Falconer N; Canaris S; Bonilla O; Marxen S; Van Garderen A; Barras M Interact J Med Res; 2022 Sep; 11(2):e34533. PubMed ID: 35993617 [TBL] [Abstract][Full Text] [Related]
2. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications. Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time. Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730 [TBL] [Abstract][Full Text] [Related]
4. Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation. Thompson MH; Wilson SH; Toussaint BL; Jordan CL; Hayes GL; McKinzie BP; Wolf BJ; Field LC J Clin Anesth; 2016 Sep; 33():346-50. PubMed ID: 27555191 [TBL] [Abstract][Full Text] [Related]
5. Systematic review of machine learning models for personalised dosing of heparin. Falconer N; Abdel-Hafez A; Scott IA; Marxen S; Canaris S; Barras M Br J Clin Pharmacol; 2021 Nov; 87(11):4124-4139. PubMed ID: 33835524 [TBL] [Abstract][Full Text] [Related]
6. Heparin dose adjustment required to maintain goal-activated partial thromboplastin time during therapeutic hypothermia. Fevold RT; Leung YT; Garofoli AC; White RD; Barsness GW; Dierkhising RA; Ou NN J Crit Care; 2015 Jun; 30(3):574-8. PubMed ID: 25746584 [TBL] [Abstract][Full Text] [Related]
7. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study. Bauer SR; Ou NN; Dreesman BJ; Armon JJ; Anderson JA; Cha SS; Oyen LJ Mayo Clin Proc; 2009 Dec; 84(12):1073-8. PubMed ID: 19955244 [TBL] [Abstract][Full Text] [Related]
8. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506 [TBL] [Abstract][Full Text] [Related]
9. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Bozovich GE; Gurfinkel EP; Antman EM; McCabe CH; Mautner B Am Heart J; 2000 Oct; 140(4):637-42. PubMed ID: 11011339 [TBL] [Abstract][Full Text] [Related]
10. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. Byun JH; Jang IS; Kim JW; Koh EH Blood Res; 2016 Sep; 51(3):171-174. PubMed ID: 27722127 [TBL] [Abstract][Full Text] [Related]
11. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the activated partial thromboplastin time and its influential factors in ischemic heart disease patients under heparin treatment. Rezagholizadeh A; Adib ZK; Entezari-Maleki T Blood Coagul Fibrinolysis; 2021 Oct; 32(7):496-503. PubMed ID: 34650022 [TBL] [Abstract][Full Text] [Related]
13. Comparison of 2 weight-based heparin dosing nomograms in neurology and vascular surgical patients. Marotti SB; Barras M; Kirkpatrick C Ther Drug Monit; 2015 Feb; 37(1):33-9. PubMed ID: 24831654 [TBL] [Abstract][Full Text] [Related]
14. Epidurals in patients receiving thromboprophylaxis with unfractionated heparin three times a day: the value of activated partial thromboplastin time testing. Pace M; Koury K; Gulur P Anesth Analg; 2014 Nov; 119(5):1215-8. PubMed ID: 25225890 [TBL] [Abstract][Full Text] [Related]
15. Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients. Al-Sallami H; Newall F; Monagle P; Ignjatovic V; Cranswick N; Duffull S Br J Clin Pharmacol; 2016 Jul; 82(1):178-84. PubMed ID: 26972703 [TBL] [Abstract][Full Text] [Related]
16. Monitoring of unfractionated heparin in critically ill patients. Aarab R; van Es J; de Pont AC; Vroom MB; Middeldorp S Neth J Med; 2013 Nov; 71(9):466-71. PubMed ID: 24218420 [TBL] [Abstract][Full Text] [Related]
17. Establishing a new target range for unfractionated heparin for acute coronary syndromes. Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747 [TBL] [Abstract][Full Text] [Related]
18. [Deviation of activated partial thromboplastin time from optimal level after 12 hours of intravenous infusion of unfractionated heparin -- an independent predictor of recurrence and unfavorable 30-day prognosis in patients with myocardial infarction]. Shalaev SV; Shava VP; Petrik ES; Pushnikova MA; Zhuravleva TD Kardiologiia; 2005; 45(10):27-30. PubMed ID: 16234765 [TBL] [Abstract][Full Text] [Related]
19. A Recurrent Neural Network Model for Predicting Activated Partial Thromboplastin Time After Treatment With Heparin: Retrospective Study. Boie SD; Engelhardt LJ; Coenen N; Giesa N; Rubarth K; Menk M; Balzer F JMIR Med Inform; 2022 Oct; 10(10):e39187. PubMed ID: 36227653 [TBL] [Abstract][Full Text] [Related]
20. Low-Dose versus Therapeutic Range Intravenous Unfractionated Heparin Prophylaxis in the Treatment of Patients with Severe Aneurysmal Subarachnoid Hemorrhage After Aneurysm Occlusion. Kunz M; Siller S; Nell C; Schniepp R; Dorn F; Huge V; Tonn JC; Pfister HW; Schichor C World Neurosurg; 2018 Sep; 117():e705-e711. PubMed ID: 29959066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]